Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care – Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results

• Published in: Diabetes research and clinical practice Vol. 170; p. 108416
• Main Authors: Goldenberg, Ronald, Bell, Alan, Cheng, Willoon, Fils-Aimé, Nadège, Burrows, Melonie, Blavignac, Jessica, Parron, Emilia, Barakat, Maxime
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.12.2020
• Subjects: Aged; Anticholesteremic Agents - therapeutic use; Antihypertensive Agents - therapeutic use; Benzimidazoles - therapeutic use; Canada; Cardiovascular Diseases - drug therapy; Cardiovascular disorders; Chlorthalidone - therapeutic use; Colesevelam Hydrochloride - therapeutic use; Diabetes Mellitus, Type 2 - drug therapy; Female; Humans; Hypercholesterolemia; Hypercholesterolemia - drug therapy; Hypertension; Hypertension - drug therapy; Hypoglycemic Agents - therapeutic use; Male; Metabolic disorders; Metabolic Syndrome - drug therapy; Metformin - therapeutic use; Middle Aged; Oxadiazoles - therapeutic use; Prospective Studies; Registries; Registry-based study; Treatment Outcome; Type 2 diabetes; Canada; Type 2 diabetes; def; MetER; MetIR; PCSK9; AZI/CHL; HDL-C; DBP; RWE; mo; AE; T2D; DCCT; AZI; CVD; ARB; Hypercholesterolemia; Cardiovascular disorders; AV; CRF; SAE; FPG; Metabolic disorders; TXC; N/A; RCT; C; HTN; LDL-C; RAASi; HCh; BP; CHEP; ESC; UKPDS; ApoB; CKD; HbA1c; BMI; Hypertension; eGFR; SBP; GI; CCB; MedDRA; CI; SOC; TC; ACR; ACS; CCS; CV; TG; ACEi; Registry-based study

•Achieving targets of cardiometabolic disease parameters crucial to delay complications.•RWE of the safety and efficacy of CV and metabolic drugs in Canada is scarce.•CV-CARE provides RWE in Canadian routine clinical care setting. The CV-CARE registry provides RWE in Canadian routine clinical practi...